Dopamine intranasal - Mattern

Drug Profile

Dopamine intranasal - Mattern

Alternative Names: DopaMat; MPP-18

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Mattern Pharmaceuticals
  • Class Antihypotensives; Cardiotonics; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease
  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 04 May 2016 Phase I development is ongoing in Switzerland
  • 20 Feb 2009 Phase-I clinical trials in Parkinson's disease in Switzerland (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top